文献速递血液透析通路

编辑推荐——单期与两期肱动脉-贵要静脉动静脉瘘的结局:一项瑞典全国登记研究

Editor's Choice - Outcomes of Single or Two Stage Brachiobasilic Arteriovenous Fistula: A Nationwide Swedish Registry Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2024-12-18

该回顾性观察研究基于瑞典肾脏登记系统,纳入2011至2019年≥18岁患者创建的肱动脉-贵要静脉动静脉瘘(BBAVF),比较单期(BB1)与两期(BB2)手术的功能结局。结果发现BB2的一年初级通畅率优于BB1(54% vs 39%,p=.002),但两期手术需两次操作;两组的次级通畅率相似,长期通畅率等效。女性及合并糖尿病的患者通畅率较差,BBAVF的可用性较低。

要点

  • BB2的一年初级通畅率为54%,高于BB1的39%(p=.002)。
  • BB1与BB2的一年和三年次级通畅率相似(BB1 81%和69%,BB2 82%和78%;p=.14)。
  • 女性及合并糖尿病的患者通畅率较差,BBAVF可用性较低。

核心结论

  • 两期方法具有更优的初级通畅率,但以两次手术为代价;两种手术技术的长期通畅率等效。
  • 血管内再干预发生率高,且BBAVF在女性和合并糖尿病的患者中可用性较低。

研究设计与样本

  • 回顾性观察研究,数据来自瑞典肾脏登记系统。
  • 纳入2011至2019年间年龄≥18岁患者创建的BBAVF,分为单期(BB1)或两期(BB2)。
  • 从创建起捕获结局、通畅性和并发症,以及所有开放和血管内重复手术。

主要发现

  • BB1(n=224)比BB2(n=83)更常见;BB2中66例(80%)在第二期进行了转位。
  • 未进行转位的最常见原因是闭塞(n=10)。
  • 中位随访时间为两年(四分位距[IQR] 0.8,4.2)。
  • 总体31%的BBAVF从未使用;静脉狭窄常见,BB1中157例(70%),BB2中40例(48%)。
  • BB1的每患者年血管内干预发生率是BB2的两倍(0.6 vs. 0.3)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Creation of a brachiobasilic arteriovenous fistula (BBAVF) can be performed as either a one or two stage procedure; however, evidence for the best technique is conflicting. The aim of this national registry review was to determine whether functional outcomes favoured either method. METHODS: This was a retrospective observational study with data from the Swedish Renal Registry. BBAVFs created in patients aged ≥ 18 years between 2011 and 2019 were included and were categorised as one stage (BB1) or two stage (BB2). Outcome, patency, and complications were captured from creation onwards, as were all open and endovascular repeat procedures. RESULTS: BB1s (n = 224) were more common than BB2s (n = 83). Of the BB2s, 66 (80%) were transposed in the second stage. The most common reason for not performing transposition was occlusion (n = 10). The median follow up was two years (interquartile range [IQR] 0.8, 4.2). Overall, 31% of BBAVFs were never used. Vein stenosis was common, seen in 157 BB1s (70%) and 40 BB2s (48%). The incidence of endovascular interventions per patient year was two times higher in BB1s than BB2s (0.6 vs. 0.3). Primary patency at one year was 39% and 54% in BB1 and BB2, respectively (p = .002). Secondary patency at one and three years was similar between groups (BB1 81% and 69%, and BB2 82% and 78%; p = .14). Diabetes as a comorbidity and female sex were associated with worse patency, but body mass index ≥ 30 kg/m2 was not. Creation pre-dialysis did not affect patency. The median time from creation to first puncture was 73 days (IQR 51, 157) and 141 days (IQR 105, 225) for BB1 and BB2, respectively. CONCLUSION: The two stage method had superior primary patency, counterbalanced by two operations. Long term patency was equivalent for the two surgical techniques. The incidence of endovascular re-interventions was high, and BBAVFs were less usable in females and patients with diabetes as a comorbidity.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Welander G, Lundin F, Palanjafi H, et al. Editor's Choice - Outcomes of Single or Two Stage Brachiobasilic Arteriovenous Fistula: A Nationwide Swedish Registry Study. Eur J Vasc Endovasc Surg. 2024. PMID: 39706326. doi:10.1016/j.ejvs.2024.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。